platinum-resistant ovarian cancerrecurrent diseaseepithelial ovarian cancersmirvetuximab soravtansinegemcitabineexatecanFDAClone 65Sanyou Biopharmaceuticals Laboratory Animal Ethics CommitteeSKOV3
…mited. While the FDA has approved mirvetuximab soravtansine for platinum-resistant ovarian cancer, its clinical performance underscores a persistent unmet need i…